PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
ABKO is pursuing a gradual earnings recovery in its core gaming gear business while simultaneously diversifying into a new medical device venture through a US biotech stake investment.
Consolidated revenue fell to KRW 83.4 billion in 2025, marking a third straight annual decline, though operating profit has remained positive since recovering from the large 2022 loss.
Third-quarter 2025 operating profit rose 43% year-on-year on a gaming gear sales surge, but the company swung back to operating losses in the fourth quarter and again in Q2 2026, underscoring earnings volatility.
In May 2026 ABKO added AI-based medical solutions and biosensors to its stated business purposes, and in July 2026 completed acquisition of a 40% stake in US medical device startup Bullseye Biodevices.
Revenue from the public-sector segment (including smart device charging cabinets for schools) fell from KRW 34.0 billion in 2024 to KRW 27.0 billion in 2025, a key driver of the overall slowdown.
Total dividends declared for fiscal 2025 significantly exceeded that year's operating profit, raising questions about the sustainability of the payout level.
Founded in 2001 and listed on KOSDAQ in December 2020, ABKO is a gaming gear and small-appliance specialist that holds a dominant number-one position in Korea's domestic gaming gear market.
Operating multiple brands including ABKO, Hacker, and Cox, the company sells keyboards, mice, headsets, broadcast equipment, PC cases, and gaming desks/chairs, with its flagship gaming keyboard reportedly commanding over 40% domestic market share.
The business is organized around three segments: gaming gear, small appliances (under the Oella brand), and public-sector contracts (including the "PADBANK" smart device charging cabinet system for schools), with gaming gear historically accounting for more than half of revenue and the public-sector segment around 40% in certain periods.
The small-appliance segment sells over 200 products—cordless vacuum cleaners, massage guns, air purifiers, and more—through channels such as Coupang, Kakao Talk Shopping, home shopping, E-mart, and Costco.
The public-sector business supplies smart device charging systems to elementary, middle, and high school classrooms nationwide, with revenue tied to local government and education office budget cycles.
More recently, the company has pursued diversification: at its May 2026 extraordinary shareholders meeting it added AI-based medical solutions, intelligent medical robotics, and biosensors to its articles of incorporation as new business purposes.
In July 2026 it completed acquisition of a 40% stake in US medical device startup Bullseye Biodevices, marking a formal entry into the medical and healthcare device market. Management control remains stable, with CEO Oh Kwang-geun and related parties holding roughly a 32% stake.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | — | — | — |
| 2025Q3 | ₩19.3B | ₩1.1B | 5.9% |
| 2025Q4 | ₩25.2B | -₩800M | −3.3% |
| 2026Q1 | ₩16.4B | ₩700M | 4.1% |
| 2026Q2 | ₩20.8B | -₩300M | −1.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩82.7B | -₩15.5B | -₩17.6B | −18.7% | −31.4% | 77.6% |
| 2023 | ₩98.9B | ₩2.2B | ₩1.8B | 2.2% | 3.1% | 65.3% |
| 2024 | ₩93.4B | ₩4.8B | ₩4.7B | 5.2% | 8.3% | 72.8% |
| 2025 | ₩83.4B | ₩3.2B | ₩6.4B | 3.8% | 10.3% | 67.1% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04
ABKO's consolidated revenue declined for three consecutive years, from KRW 98.9 billion in 2023 to KRW 93.4 billion in 2024 and KRW 83.4 billion in 2025.
Operating profit, meanwhile, recovered from a massive KRW 15.5 billion loss in 2022 to KRW 2.2 billion in 2023 and KRW 4.8 billion in 2024, before slipping back to KRW 3.2 billion in 2025 as the operating margin narrowed from 5.2% to 3.8%.
Net income attributable to owners improved every year from a KRW 17.6 billion loss in 2022 to KRW 1.8 billion in 2023, KRW 4.7 billion in 2024, and KRW 6.4 billion in 2025.
On a quarterly basis, third-quarter 2025 revenue of KRW 19.3 billion and operating profit of KRW 1.1 billion rose 43% year-on-year on a gaming gear sales surge, but the fourth quarter reverted to an operating loss of KRW 0.8 billion despite revenue of KRW 25.2 billion.
Fourth-quarter net income of KRW 2.3 billion diverged sharply from the operating loss, suggesting non-operating items had a substantial impact on that period's results.
In the first quarter of 2026, revenue was KRW 16.4 billion with operating profit of KRW 0.7 billion and net income of KRW 2.8 billion, with roughly KRW 2.4 billion in other income tied to a fixed-asset disposal cited as a one-off contributor to the net profit figure.
In the second quarter of 2026, revenue reached KRW 20.8 billion, yet the company posted an operating loss of KRW 0.3 billion and a net loss of KRW 0.8 billion, extending the pattern of volatile recent quarterly results.
On the cash flow side, 2025 operating cash flow of KRW 11.1 billion exceeded net income, while 2024 operating cash flow was negative KRW 8.2 billion, moving in the opposite direction of that year's net income—highlighting significant year-to-year swings in cash generation.
The gaming gear industry has expanded on the back of e-sports growth and home-gaming trends, but the number of PC gaming cafes ('PC bang'), a key domestic demand driver, has structurally declined since the pandemic and has not returned to pre-pandemic levels.
More recently, however, an expansion of premium PC bang formats has been observed, partially offsetting the broader decline in PC bang numbers. In addition, the spread of K-pop and Korean content, along with rising numbers of foreign tourists and the popularity of content such as "KPop Demon Hunters,
At its May 2026 extraordinary shareholders meeting, ABKO added seven new business purposes to its articles of incorporation—including AI-based medical solutions, intelligent medical robotics, and biosensors—and at the same time decided to acquire a 40% stake in US medical device startup Bullseye Biodevices.
That investment was finalized in July 2026 following the signing of a new-share subscription agreement and transfer of funds; the company stated it aims to leverage Bullseye's patent portfolio for biosensors mounted on surgical robots, targeting precision cancer surgeries (lung, liver, colorectal) initially before expanding into regenerative medicine and cardiovascular disease applications.
Bullseye is working with a Stanford Medical School research team on tissue analysis and clinical development toward US FDA approval, though a specific regulatory timeline and clinical stage have not yet been disclosed.
To fund the new venture, the company sold a property in Gimpo, Gyeonggi Province for KRW 8.0 billion at the end of 2025, receiving final payment in January 2026, and in February 2026 refinanced by securing a KRW 14.0 billion short-term loan from Shinhan Bank at a lower interest rate to repay existing borrowings.
The core gaming gear business rebounded in the third quarter of 2025 on premium PC bang expansion and strong sales of K-content-related merchandise, and whether this momentum persists will be a key variable for future results.
The public-sector segment is expected to continue showing significant quarter-to-quarter revenue swings tied to budget allocation cycles, while the new biosensor business is expected to require time before reaching commercialization.
In a past securities-industry report, ABKO was noted as trading at roughly 7-8 times projected 2024 earnings and about 0.8 times book value, both below the then-KOSDAQ average multiples of over 20 times earnings and over 2 times book value.
The stock continues to trade at a discount to net asset value, a valuation pattern often seen among small-cap hardware manufacturers with volatile earnings.
Net income has improved every year since the large 2022 loss, but quarterly operating results have alternated between profit and loss, which may lead the market to take differing views on the quality and sustainability of that earnings improvement.
That total dividends declared for fiscal 2025 exceeded that year's operating profit can be viewed positively from a shareholder-return perspective, but the fact that a meaningful portion of the funding came from a one-off property sale is a factor worth weighing when assessing the sustainability of future payouts.
The newly entered biosensor business remains at an early, pre-revenue stage, so there is currently limited financial basis for it to be reflected in valuation.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04
Gaming gear revenue grew more than 40% year-on-year in the third quarter of 2025, lifting operating profit by 43%. Growth was supported by expansion of the premium PC bang market and strong sales of merchandise tied to the spread of Korean cultural content.
With more than 40% share of the domestic gaming keyboard market, a recovery in related demand could translate into further improvement in core profitability.
In 2026 the company acquired a 40% stake in US medical device startup Bullseye Biodevices, gaining access to biosensor technology mounted on surgical robots.
The global surgical robot market is projected to grow from USD 6.6 billion in 2025 to USD 18.5 billion by 2033, and successful commercialization could become a new growth driver. ABKO's accumulated mass-production know-how in electronics manufacturing is also cited as a potential strength for this new venture.
A late-2025 property sale generated KRW 8.0 billion in funding, and in February 2026 the company refinanced borrowings at a lower interest rate, improving financial flexibility. The CEO and related parties hold a stable roughly 32% stake supporting management continuity.
Total dividends declared for fiscal 2025 exceeded operating profit, reflecting an active approach to shareholder returns.
Consolidated revenue declined steadily from KRW 98.9 billion in 2023 to KRW 83.4 billion in 2025, driven in large part by the public-sector education segment falling from KRW 34.0 billion in 2024 to KRW 27.0 billion in 2025.
PC bang demand also has not recovered to pre-pandemic levels, leaving a structural constraint on core business growth.
In both the fourth quarter of 2025 and the second quarter of 2026, the company posted operating losses despite revenue growth.
Net income has been heavily influenced by non-operating items such as fixed-asset disposal gains, suggesting a stable earnings structure driven purely by core operations has not yet been firmly established.
Bullseye Biodevices is an early-stage startup founded in 2024, and its FDA approval timeline, clinical stage, and specific investment scale have not yet been disclosed.
Given the technological and regulatory differences from gaming gear and hardware manufacturing, meaningful synergy realization is expected to take considerable time.
The Bullseye investment is a stake in an early-stage startup; delays or failures in FDA approval or clinical progress could affect the recovery of invested capital.
Because gaming gear and electronics differ substantially from medical devices in regulatory framework and business practices, management's ability to oversee the new venture will be tested.
The gaming gear business depends heavily on the PC bang industry, while the public-sector segment relies on local government and education office budget allocations.
PC bang demand has not yet recovered to pre-pandemic levels, and public-sector revenue has recently declined due to reduced budgets, leaving both pillars sensitive to external variables.
Total dividends declared for fiscal 2025 significantly exceeded that year's operating profit, with a substantial portion of the funding sourced from one-off items such as a property sale. Absent similar one-off funding going forward, there is a possibility the dividend size or policy could be adjusted.
The provisional third-quarter earnings release will be worth checking to see whether gaming gear revenue growth continues and whether the public-sector segment shows signs of recovery.
New procurement orders and budget announcements for public education projects, such as school smart-device charging cabinets, could shape that segment's revenue trajectory.
Progress on Bullseye Biodevices' FDA approval and clinical development, along with any disclosures on additional investment or technology licensing, will need ongoing monitoring.
The board's decision on the fiscal 2026 dividend will reveal whether the high-payout policy seen in fiscal 2025 continues.
Backed by its number-one position in Korea's domestic gaming gear market, ABKO showed signs of a rebound from the third quarter of 2025, but quarterly earnings volatility has persisted, with the company posting operating losses again in the fourth quarter of 2025 and the second quarter of 2026.
A decline in public-sector segment revenue has been a key driver of three consecutive years of overall revenue decline, and net income has relied considerably on non-operating factors such as fixed-asset disposal gains.
In 2026 the company diversified into the medical and bio field by acquiring a 40% stake in US medical device startup Bullseye Biodevices, though this remains at an early stage with no confirmed revenue contribution or specific regulatory timeline yet.
Financially, the company secured funding and liquidity for the new venture through a property sale and low-interest refinancing, and for fiscal 2025 it declared dividends exceeding that year's operating profit.
Overall, a gradual recovery in core earnings coexists with a new diversification effort, leaving the quality and sustainability of results and the timing of new-business commercialization as key variables to watch going forward.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.